Boges

Complete nonsense.  There has been a bit of a price break because the government is buying in massive quantities.  If the government decides to do the same with the prescription it would negotiate for similar discounts.  Regardless, company’s drug patent expires in a short period of time.  After that, the drug for them becomes unprofitable.  So getting as much as you can, to pay for your expenses and to research and develop new drugs is paramount.  

New analysis by the Alliance shows that the firms Pfizer/BioNTech and Moderna are charging governments as much as $41 billion above the estimated cost of production. Colombia, for example, has potentially overpaid by as much as $375 million for its doses of the Pfizer/BioNTech and Moderna vaccines, in comparison to the estimated cost price.

https://www.oxfam.org/en/press-releases/vaccine-monopolies-make-cost-vaccinating-world-against-covid-least-5-times-more

 

From the article you posted. 

Quote

The highest reported price paid for Pfizer/BioNTech vaccines was paid by Israel at $28 a dose ―nearly 24 times the potential production cost.

From the article I posted. 

Quote

 

A FIVE-DAY COURSE of molnupiravir, the new medicine being hailed as a “huge advance” in the treatment of Covid-19, costs $17.74 to produce, according to a report issued last week by drug pricing experts at the Harvard School of Public Health and King’s College Hospital in London. Merck is charging the U.S. government $712

 

See the difference? If you don't you don't do math well. 

The article you post is more concerned with distributing the vaccine the third world where even $30-40$ per vaccination is too much. They need it for next to free. 

You still don’t understand.  The patent and regulatory process per drug usually costs between $500 million and a billion dollars. That doesn’t even count the research and development.  Your costing the cost of the physical production of the pill, not everything they went into it.

Regardless, move to Venezuela if you don’t like capitalism.  
 

From the article you cited:

Melissa Barber, a doctoral candidate at the Harvard School of Public Health and co-author of the report on molnupiravir, said that, while its pricing is not as extreme as that of some other drugs